Previous Article | Next Article ![]()
Infection and Immunity, June 2002, p. 3122-3129, Vol. 70, No. 6
0019-9567/02/$04.00+0 DOI: 10.1128/IAI.70.6.3122-3129.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.
Immunologie des Leishmanioses,1 Service d'Epidémiologie, Institut Pasteur de Cayenne, 97306 Cayenne Cedex,2 Institut Guyanais de Dermatologie Tropicale E.A. 2188, Centre Hospitalier Andrée Rosemon, 97300 Cayenne, French Guiana,3 Ehime University School of Medicine, Shigenobu, Ehime, Japan,4 Immunophysiologie et Parasitisme Intra-cellulaire, Institut Pasteur de Paris, 75024 Paris Cedex 15, France5
Received 19 December 2001/ Returned for modification 2 February 2002/ Accepted 12 March 2002
The profile of cytokines induced by soluble leishmania antigen (SLA) and the Leishmania homologue of the mammalian receptor for activated C kinase (LACK), a candidate vaccine against leishmaniasis, and the cellular source of the cytokines produced in response to these antigens were analyzed in patients infected with Leishmania guyanensis. Gamma interferon (IFN-
) and interleukin-10 (IL-10) were produced in response to LACK. Although LACK-specific CD4+ cells producing IFN-
were isolated only during the early phase of infection (less than 30 days following the onset of infection), cells producing IL-10 in response to LACK were detected in all patients. CD4+ T cells producing IFN-
and IL-13 were produced in response to SLA in all patients. SLA- and LACK-specific T cells are effector memory cells, as they are CD45RA- CCR7- CD4+ T cells. CD4+ T cells producing IFN-
are CD62L-, and CD4+ T cells producing IL-10 are CD62L+, indicating that these cells have different tissue-homing capacities. These findings show that SLA and LACK induce both type 1 (IFN-
) and type 2 (IL-10 or IL-13) cell responses.
This article has been cited by other articles:
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»